Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment

Hemasphere. 2022 Jul 4;6(7):e749. doi: 10.1097/HS9.0000000000000749. eCollection 2022 Jul.

Esther E E Drees^{1

2}, Yvonne W S Jauw^{2

3}, Erik van Dijk^{1

2}, Sven Borchmann⁴, Sandra A W M Verkuijlen^{1

2}, Phylicia Stathi^{1

2}, Nils J Groenewegen^{1

2

5}, Nathalie J Hijmering^{1

2}, Daniella R A I Berry^{1

2}, Eric J Meershoek⁶, Danielle Hoogmoed⁶, Anne Kwakman^{1

2}, Tessa J Molenaar^{1

2}, Dirk M Pegtel^{1

2}, Bauke Ylstra^{1

2}, Daphne de Jong^{1

2}, Josée M Zijlstra^{2

3}, Margaretha G M Roemer^{1

2}

¹ Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
² Program Imaging and Biomarkers, Cancer Center Amsterdam, The Netherlands.
³ Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
⁴ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
⁵ ExBiome B. V., Amsterdam, The Netherlands.
⁶ Leica Biosystems/Kreatech Diagnostics B.V., Amsterdam, The Netherlands.

No abstract available